Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
New insights into COVID-19 infectiousness
Fri August 19th - British researchers have unveiled the first real-world study to estimate how long people are infectious with mild COVID-19. More
Gene variant that protects against heart disease
Fri August 19th - A gene variant has been identified that helps to protect against heart diseases. More
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...

Rheumatic heart disease breakthrough

Friday March 25th 2022

Six newly identified proteins, implicated in rheumatic heart disease, could herald a change in the way the condition is treated and diagnosed in the developing world, researchers say.

A study, undertaken by the University of Manchester, UK, and the University of Cape Town, South Africa, used proteomics to identify the disease’s biomarker signature.

Writing in *Clinical Proteomics*, the authors say their findings show, for the first time, ongoing inflammation activity in 215 patients with severe RHD from 10 African countries.

The team took blood samples from participating RHD patients in the RHDGen Consortium, which is led by Dr Mark Engel and the late Prof Bongani Mayosi at the University of Cape Town.

They analysed about 2,500 proteins implicated in RHS and when they used machine learning to proteomic data, they identified six that gave a 90% discrimination rate.

RHD is caused by one or several episodes of rheumatic fever, caused by Streptococcus pyogenes. Although it is the only cardiovascular disease of global impact that is completely preventable, developing countries have poor access to echocardiography to diagnose it early enough to treat it.

The research team say identifying the biomarker signature could help in the development of simple test kits that could be used in the home and clinic and they add that existing anti-inflammatory treatments have the potential to be repurposed, to be taken prophylactically to combat persistent inflammation and prevent disease progression.

Joint senior author Bernard Keavney, clinical professor of cardiovascular medicine at The University of Manchester and consultant cardiologist at Manchester University NHS Foundation trust, said: “Rheumatic heart disease is a major source of morbidity and mortality in developing countries.

“Almost 300,000 people die from this disease every year and 40 million people are profoundly affected by it. That’s a tragedy as it is essentially preventable if diagnosed early enough.

“But by providing a deeper insight into the mechanisms underlying RHD we hope now to be opening the door to new opportunities for drug repurposing, prophylaxis, and development of easy to use diagnostics.”

Taariq Salie M, Yang J, Ramírez Medina CR et al. Data independent acquisition mass spectrometry in severe Rheumatic Heart Disease (RHD) identifies a proteomic signature showing ongoing inflammation and effectively classifying RHD cases. *Clinical Proteomics* 22 March 2022


Tags: Africa | Heart Health | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)